Participants with solid tumor received E7090 1 milligram (mg) capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 2 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 4 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 8 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 16 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 30 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 60 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 100 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 140 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 180 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with gastric cancer received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with Cholangiocarcinoma received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with gastric cancer received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with Cholangiocarcinoma received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with gastric cancer received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with Cholangiocarcinoma received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 1 milligram (mg) capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 2 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 4 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 8 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 16 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 30 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 60 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 100 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 140 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 180 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with gastric cancer received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with Cholangiocarcinoma received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with gastric cancer received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with Cholangiocarcinoma received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with gastric cancer received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with Cholangiocarcinoma received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 1 milligram (mg) capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 2 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 4 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 8 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 16 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 30 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 60 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 100 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 140 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 180 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with gastric cancer received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with Cholangiocarcinoma received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 1 milligram (mg) capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 2 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 4 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 8 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 16 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 30 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 60 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 100 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 140 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 180 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with gastric cancer received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with Cholangiocarcinoma received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 1 milligram (mg) capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 2 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 4 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 8 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 16 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 30 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 60 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 100 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 140 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 180 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with gastric cancer received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with Cholangiocarcinoma received E7090 140 mg capsules orally, on Days 1 and 8 of Cycle 1 in the fasting state and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 1 milligram (mg) capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 2 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 4 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 8 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 16 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in 28-days treatment cycles for Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 30 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 60 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 100 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 140 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.

Participants with solid tumor received E7090 180 mg capsules orally, once on Day 1 of Cycle 0 (Cycle length=7 days) in the fasting state and thereafter once daily in Cycle 1 and 2 and subsequent cycles (Cycle length=28 days) unless withdrawal of consent, major inclusion/exclusion criteria violation, difficulty in continuing the study due to an adverse event, pregnancy, disease progression, dose reduction to <1 mg (Part 1) or <35 mg (Part 2) required due to an adverse drug reaction, other cases where the investigator or subinvestigator considers study discontinuation appropriate.